Until recently, there was no access to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for Welsh patients with resectable colorectal peritoneal metastases. A pilot programme, funded by Moondance Cancer… Click to show full abstract
Until recently, there was no access to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for Welsh patients with resectable colorectal peritoneal metastases. A pilot programme, funded by Moondance Cancer Initiative, aimed to improve colorectal peritoneal metastases management and offer CRS and HIPEC to selected patients. Service development strategies and short‐term outcomes are presented.
               
Click one of the above tabs to view related content.